aliskiren ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
renin inhibitors 119 173334-57-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aliskiren
  • rasilez
  • tekturna
  • aliskiren hemifumarate
  • aliskiren fumarate
  • SPP100
Renin is secreted by the kidney in response to decreases in blood volume and renal perfusion. Renin cleaves angiotensinogen to form the inactive decapeptide angiotensin I (Ang I). Ang I is converted to the active octapeptide angiotensin II (Ang II) by ACE and non-ACE pathways. Ang II is a powerful vasoconstrictor and leads to the release of catecholamines from the adrenal medulla and prejunctional nerve endings. It also promotes aldosterone secretion and sodium reabsorption. Together, these effects increase blood pressure. Ang II also inhibits renin release, thus providing a negative feedback to the system. This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS). Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.
  • Molecular weight: 551.77
  • Formula: C30H53N3O6
  • CLOGP: 3.51
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 4
  • TPSA: 146.13
  • ALOGS: -5.42
  • ROTB: 19

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 g O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 7.77 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
S (Water solubility) 100 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 25 % Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 2.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Aug. 22, 2007 EMA Noden Pharma DAC
March 5, 2007 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neurologic neglect syndrome 556.63 23.99 119 9474 2602 63476827
Carotid artery thrombosis 553.50 23.99 119 9474 2675 63476754
Personality disorder 551.65 23.99 136 9457 5675 63473754
Adjustment disorder 499.76 23.99 112 9481 3066 63476363
Hemiplegia 492.47 23.99 137 9456 9186 63470243
Affect lability 468.21 23.99 137 9456 11014 63468415
Sensory loss 408.80 23.99 121 9472 10117 63469312
Motor dysfunction 394.22 23.99 119 9474 10642 63468787
Muscle spasticity 374.25 23.99 136 9457 21658 63457771
Coordination abnormal 369.36 23.99 120 9473 13653 63465776
Hemiparesis 350.88 23.99 132 9461 23150 63456279
Aphasia 339.55 23.99 142 9451 32858 63446571
Eating disorder 312.82 23.99 115 9478 18901 63460528
Cerebrovascular accident 291.79 23.99 189 9404 107835 63371594
Dysarthria 282.81 23.99 135 9458 42576 63436853
Dysphagia 244.02 23.99 157 9436 88428 63391001
Blood pressure inadequately controlled 177.69 23.99 54 9539 4924 63474505
Muscular weakness 177.14 23.99 147 9446 122206 63357223
Skin haemorrhage 140.28 23.99 54 9539 10040 63469389
Anxiety 119.04 23.99 155 9438 217386 63262043
Angioedema 105.41 23.99 74 9519 47891 63431538
Respiratory tract congestion 104.75 23.99 52 9541 17780 63461649
Sinus congestion 103.95 23.99 52 9541 18071 63461358
Sneezing 103.69 23.99 52 9541 18166 63461263
Confusional state 103.11 23.99 151 9442 236229 63243200
Diabetes mellitus inadequate control 91.48 23.99 45 9548 15081 63464348
Conjoined twins 91.02 23.99 18 9575 262 63479167
Sinus disorder 89.12 23.99 52 9541 24501 63454928
Blood pressure increased 80.13 23.99 110 9483 161952 63317477
Impaired work ability 76.92 23.99 42 9551 17433 63461996
Skin exfoliation 73.30 23.99 57 9536 43045 63436384
Arterial occlusive disease 72.64 23.99 29 9564 5929 63473500
Off label use 69.14 23.99 10 9583 674452 62804977
Intestinal malrotation 68.55 23.99 15 9578 365 63479064
Concomitant disease progression 67.05 23.99 21 9572 2113 63477316
Congenital bladder anomaly 66.96 23.99 13 9580 171 63479258
Urachal abnormality 66.40 23.99 13 9580 179 63479250
Persistent cloaca 65.55 23.99 13 9580 192 63479237
Cystitis 65.10 23.99 59 9534 54932 63424497
Gangrene 65.05 23.99 27 9566 6096 63473333
Angina pectoris 62.80 23.99 45 9548 30033 63449396
Asthenia 60.97 23.99 160 9433 383444 63095985
Fall 59.68 23.99 161 9432 392173 63087256
Influenza like illness 55.38 23.99 59 9534 66765 63412664
Exercise tolerance decreased 50.94 23.99 22 9571 5475 63473954
Multiple drug therapy 48.84 23.99 19 9574 3627 63475802
Rhinorrhoea 47.57 23.99 54 9539 65523 63413906
Hyperkalaemia 45.15 23.99 48 9545 54155 63425274
Blood creatinine increased 39.44 23.99 57 9536 87787 63391642
Anal prolapse 36.49 23.99 7 9586 86 63479343
Psoriasis 35.55 23.99 54 9539 86903 63392526
Drug intolerance 32.91 23.99 4 9589 308657 63170772
Influenza 30.43 23.99 57 9536 108665 63370764
Toxicity to various agents 26.86 23.99 3 9590 247247 63232182
Arthralgia 26.81 23.99 28 9565 569682 62909747
Gastric disorder 25.78 23.99 30 9563 37339 63442090
Infusion related reaction 24.25 23.99 4 9589 245517 63233912

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Concomitant disease progression 291.45 20.25 68 4769 2450 34949644
Blood creatinine increased 106.76 20.25 95 4742 94881 34857213
Hyperkalaemia 89.22 20.25 75 4762 69314 34882780
Urine albumin/creatinine ratio increased 52.04 20.25 11 4826 248 34951846
Renal impairment 50.98 20.25 64 4773 94449 34857645
Chronic kidney disease 49.72 20.25 43 4794 41167 34910927
Blood pressure inadequately controlled 48.68 20.25 17 4820 2623 34949471
Angina pectoris 42.50 20.25 35 4802 31328 34920766
Blood potassium increased 42.05 20.25 27 4810 16468 34935626
Blood pressure increased 40.25 20.25 55 4782 88047 34864047
Angioedema 35.29 20.25 34 4803 37340 34914754
Bundle branch block left 35.24 20.25 17 4820 5962 34946132
Disease progression 33.07 20.25 56 4781 108021 34844073
Diabetic nephropathy 32.80 20.25 12 4825 2116 34949978
Hypotension 32.63 20.25 85 4752 221564 34730530
Off label use 32.52 20.25 9 4828 419515 34532579
Glycosylated haemoglobin increased 32.48 20.25 20 4817 11340 34940754
Oedema peripheral 30.14 20.25 57 4780 119755 34832339
Post procedural haematoma 28.80 20.25 10 4827 1516 34950578
Cardiac failure acute 28.67 20.25 18 4819 10552 34941542
Blood urea increased 27.49 20.25 27 4810 30337 34921757
Acute pulmonary oedema 26.42 20.25 15 4822 7328 34944766
Dyspnoea 26.15 20.25 112 4725 376670 34575424
Bundle branch block right 26.09 20.25 15 4822 7501 34944593
Orthopnoea 25.59 20.25 13 4824 5090 34947004
Syncope 24.85 20.25 45 4792 91406 34860688
Renal failure 24.44 20.25 55 4782 130502 34821592
Cardiac failure chronic 22.85 20.25 14 4823 7865 34944229
Defect conduction intraventricular 22.61 20.25 6 4831 366 34951728
Oedema 21.52 20.25 29 4808 45712 34906382
Atrioventricular block first degree 20.73 20.25 12 4825 6080 34946014
Myocardial ischaemia 20.64 20.25 18 4819 17390 34934704
Cerebral arteriosclerosis 20.48 20.25 6 4831 526 34951568

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neurologic neglect syndrome 549.65 22.00 118 11275 2789 79730206
Carotid artery thrombosis 549.51 22.00 119 11274 2934 79730061
Personality disorder 546.44 22.00 135 11258 6011 79726984
Adjustment disorder 474.97 22.00 111 11282 3889 79729106
Affect lability 465.43 22.00 135 11258 11124 79721871
Hemiplegia 427.77 22.00 135 11258 14804 79718191
Muscle spasticity 379.70 22.00 135 11258 21340 79711655
Sensory loss 374.42 22.00 118 11275 12873 79720122
Motor dysfunction 359.81 22.00 118 11275 14615 79718380
Coordination abnormal 348.91 22.00 120 11273 17192 79715803
Concomitant disease progression 312.19 22.00 77 11316 3396 79729599
Eating disorder 309.50 22.00 115 11278 20582 79712413
Hemiparesis 307.16 22.00 131 11262 33602 79699393
Aphasia 296.54 22.00 141 11252 46591 79686404
Dysarthria 239.35 22.00 138 11255 67484 79665511
Dysphagia 219.60 22.00 163 11230 121973 79611022
Cerebrovascular accident 209.65 22.00 175 11218 155117 79577878
Blood pressure inadequately controlled 156.89 22.00 51 11342 6126 79726869
Muscular weakness 143.98 22.00 144 11249 160585 79572410
Skin haemorrhage 123.93 22.00 51 11342 11930 79721065
Anxiety 103.68 22.00 151 11242 248361 79484634
Sneezing 102.62 22.00 52 11341 19631 79713364
Sinus congestion 99.19 22.00 51 11342 19845 79713150
Respiratory tract congestion 99.05 22.00 51 11342 19903 79713092
Angioedema 94.84 22.00 82 11311 75953 79657042
Sinus disorder 93.36 22.00 51 11342 22413 79710582
Hyperkalaemia 90.59 22.00 96 11297 114302 79618693
Off label use 80.71 22.00 16 11377 907199 78825796
Angina pectoris 75.27 22.00 61 11332 51671 79681324
Impaired work ability 74.44 22.00 42 11351 19639 79713356
Confusional state 72.68 22.00 148 11245 317849 79415146
Diabetes mellitus inadequate control 68.81 22.00 43 11350 24221 79708774
Arterial occlusive disease 64.41 22.00 29 11364 8427 79724568
Blood creatinine increased 62.80 22.00 93 11300 154964 79578031
Blood pressure increased 60.10 22.00 108 11285 211252 79521743
Cystitis 59.99 22.00 54 11339 52678 79680317
Skin exfoliation 57.95 22.00 54 11339 55046 79677949
Gangrene 56.62 22.00 27 11366 8937 79724058
Asthenia 51.32 22.00 175 11218 511514 79221481
Influenza like illness 51.17 22.00 57 11336 71650 79661345
Fall 44.75 22.00 162 11231 487467 79245528
Multiple drug therapy 44.35 22.00 18 11375 4060 79728935
Renal impairment 42.75 22.00 79 11314 157704 79575291
Rhinorrhoea 41.92 22.00 53 11340 76021 79656974
Diabetic nephropathy 39.03 22.00 15 11378 2932 79730063
Exercise tolerance decreased 38.80 22.00 21 11372 9050 79723945
Toxicity to various agents 38.29 22.00 7 11386 421533 79311462
Anal prolapse 38.02 22.00 7 11386 72 79732923
Chronic kidney disease 36.30 22.00 46 11347 66108 79666887
Oedema peripheral 33.27 22.00 95 11298 252193 79480802
Psoriasis 32.37 22.00 51 11342 89536 79643459
Condition aggravated 28.87 22.00 18 11375 501106 79231889
Neutropenia 27.85 22.00 4 11389 287706 79445289
Renal failure 26.79 22.00 76 11317 200892 79532103
Gastric disorder 25.40 22.00 29 11364 37404 79695591
Pharyngeal oedema 25.38 22.00 20 11373 16252 79716743
Influenza 24.55 22.00 56 11337 129550 79603445
Bundle branch block left 24.36 22.00 17 11376 11496 79721499
Post procedural haematoma 23.91 22.00 10 11383 2432 79730563
Rectocele 23.62 22.00 7 11386 618 79732377
Glycosylated haemoglobin increased 22.44 22.00 20 11373 19240 79713755

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09DX02 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs), other combinations
ATC C09XA02 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
Renin-inhibitors
ATC C09XA52 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
Renin-inhibitors
ATC C09XA53 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
Renin-inhibitors
ATC C09XA54 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
Renin-inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
MeSH PA D000092502 Renin Inhibitors
FDA MoA N0000175899 Renin Inhibitors
FDA EPC N0000175900 Renin Inhibitor
CHEBI has role CHEBI:35674 antihypertensive drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Obstruction of bile duct contraindication 30144000
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic idiopathic constipation contraindication 82934008
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Azotemia contraindication 445009001
Severe Aortic Valve Stenosis contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.53 acidic
pKa2 9.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Renin Enzyme INHIBITOR IC50 9.22 WOMBAT-PK CHEMBL
Multidrug resistance protein 1 Transporter Km 5.68 WOMBAT-PK
Cytochrome P450 3A4 Enzyme Km 4.61 WOMBAT-PK
Renin Enzyme IC50 8.70 CHEMBL
Renin Enzyme IC50 8.10 CHEMBL
Renin Enzyme IC50 7.10 CHEMBL
Renin-1 Enzyme IC50 8.35 CHEMBL
Renin Enzyme IC50 7.96 CHEMBL
Protease Enzyme Ki 7.12 CHEMBL
Renin Enzyme IC50 8.92 CHEMBL

External reference:

IDSource
4025960 VUID
N0000179765 NUI
D03208 KEGG_DRUG
173334-58-2 SECONDARY_CAS_RN
325646 RXNORM
C1120110 UMLSCUI
CHEBI:601027 CHEBI
C41 PDB_CHEM_ID
CHEMBL1639 ChEMBL_ID
CHEMBL3545059 ChEMBL_ID
CHEMBL1667 ChEMBL_ID
DB09026 DRUGBANK_ID
C446481 MESH_SUPPLEMENTAL_RECORD_UI
4812 IUPHAR_LIGAND_ID
7992 INN_ID
502FWN4Q32 UNII
5493444 PUBCHEM_CID
425981005 SNOMEDCT_US
426725002 SNOMEDCT_US
427002003 SNOMEDCT_US
4025960 VANDF
4030489 VANDF
108166 MMSL
23512 MMSL
310257 MMSL
34310 MMSL
d06665 MMSL
011991 NDDF
011995 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ALISKIREN HUMAN PRESCRIPTION DRUG LABEL 1 49884-424 TABLET, FILM COATED 150 mg ORAL ANDA 29 sections
ALISKIREN HUMAN PRESCRIPTION DRUG LABEL 1 49884-425 TABLET, FILM COATED 300 mg ORAL ANDA 29 sections
Tekturna HUMAN PRESCRIPTION DRUG LABEL 1 50090-2985 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
Tekturna HUMAN PRESCRIPTION DRUG LABEL 1 50090-2985 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
Tekturna HUMAN PRESCRIPTION DRUG LABEL 1 54868-5772 TABLET, FILM COATED 150 mg ORAL NDA 29 sections
Tekturna HCT HUMAN PRESCRIPTION DRUG LABEL 2 54868-6041 TABLET, FILM COATED 150 mg ORAL NDA 28 sections
Tekturna HUMAN PRESCRIPTION DRUG LABEL 1 54868-6042 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
Tekturna HCT HUMAN PRESCRIPTION DRUG LABEL 2 54868-6103 TABLET, FILM COATED 300 mg ORAL NDA 28 sections
Tekturna HCT HUMAN PRESCRIPTION DRUG LABEL 2 54868-6194 TABLET, FILM COATED 300 mg ORAL NDA 28 sections
Aliskiren HUMAN PRESCRIPTION DRUG LABEL 1 66993-141 TABLET, FILM COATED 150 mg ORAL NDA authorized generic 28 sections
Aliskiren HUMAN PRESCRIPTION DRUG LABEL 1 66993-141 TABLET, FILM COATED 150 mg ORAL NDA authorized generic 28 sections
Aliskiren HUMAN PRESCRIPTION DRUG LABEL 1 66993-142 TABLET, FILM COATED 300 mg ORAL NDA authorized generic 28 sections
Aliskiren HUMAN PRESCRIPTION DRUG LABEL 1 66993-142 TABLET, FILM COATED 300 mg ORAL NDA authorized generic 28 sections
Tekturna HCT HUMAN PRESCRIPTION DRUG LABEL 2 70839-112 TABLET, FILM COATED 150 mg ORAL NDA 29 sections
Tekturna HCT HUMAN PRESCRIPTION DRUG LABEL 2 70839-112 TABLET, FILM COATED 150 mg ORAL NDA 29 sections
Tekturna HCT HUMAN PRESCRIPTION DRUG LABEL 2 70839-125 TABLET, FILM COATED 150 mg ORAL NDA 29 sections
Tekturna HCT HUMAN PRESCRIPTION DRUG LABEL 2 70839-125 TABLET, FILM COATED 150 mg ORAL NDA 29 sections
Tekturna HUMAN PRESCRIPTION DRUG LABEL 1 70839-150 TABLET, FILM COATED 150 mg ORAL NDA 28 sections
Tekturna HUMAN PRESCRIPTION DRUG LABEL 1 70839-150 TABLET, FILM COATED 150 mg ORAL NDA 28 sections
Tekturna HUMAN PRESCRIPTION DRUG LABEL 1 70839-300 TABLET, FILM COATED 300 mg ORAL NDA 28 sections
Tekturna HUMAN PRESCRIPTION DRUG LABEL 1 70839-300 TABLET, FILM COATED 300 mg ORAL NDA 28 sections
Tekturna HCT HUMAN PRESCRIPTION DRUG LABEL 2 70839-312 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
Tekturna HCT HUMAN PRESCRIPTION DRUG LABEL 2 70839-312 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
Tekturna HCT HUMAN PRESCRIPTION DRUG LABEL 2 70839-325 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
Tekturna HCT HUMAN PRESCRIPTION DRUG LABEL 2 70839-325 TABLET, FILM COATED 300 mg ORAL NDA 29 sections